Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Figure Technology Solutions Inc. Class A Common Stock (FIGR) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance

Figure Technology Solutions Inc. Class A Common StockTrade
Relay Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Figure Technology Solutions Inc. Class A Common Stock vs Relay Therapeutics Inc. Common Stock — how do they compare? Figure Technology Solutions Inc. Class A Common Stock trades at $28.2 (market cap $6.19B), while Relay Therapeutics Inc. Common Stock trades at $17.84 (market cap $3.82B). The key difference: Figure Technology Solutions Inc. Class A Common Stock is the larger of the two by market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, Figure Technology Solutions Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figure Technology Solutions Inc. Class A Common Stock for 0 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.

FIGRRLAY
Market Cap
$6.19B$3.82B
Volume
4,762,3424,332,079
Sector
FinancialsHealth
52-Week High
$73.91$20.75
52-Week Low
$24.91$6.03
Typical Hold Time
0 Days0 Days
Enterprise Value
$6.23B$2.93B

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FIGR
100% Buy0% Sell
Avg holding period · 0 Days
RLAY
100% Buy0% Sell
Avg holding period · 0 Days

About Figure Technology Solutions Inc. Class A Common Stock

Figure Technology Solutions operates a blockchain-native capital marketplace. Its platform supports loan origination, funding, sale, and trading of tokenized assets, along with digital-asset infrastructure and services.

Read more on FIGR →

About Relay Therapeutics Inc. Common Stock

Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.

Read more on RLAY →